Seed Round - GentiBio
Investment Firm
Overview
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
Announced Date
Aug 05, 2020
Funding Type
Seed
Highlights
Location
United States, North America
Social
Investor Lead
Novartis Venture Fund
Novartis Venture Fund is a early_stage_venture and late_stage_venture and post_ipo and seed firm.
OrbiMed
OrbiMed is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
RA Capital Management
RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Participant Investors
3
| Investor Name |
|---|
 Novartis Venture Fund |
Round Details and Background
GentiBio raised $20000000 on 2020-08-05 in Seed Round
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
Company Funding History
2
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Aug 05, 2020 |  Seed Round - GentiBio | 3 | - | 20.0M |
| Aug 11, 2021 | Series A - GentiBio | 7 | - | 157.0M |
Recent Activity
There is no recent news or activity for this profile.